Rallybio is a privately-held early-stage biotechnology company incorporated in January 2018 and based in Farmington, Connecticut.
Our ambition is to create a world-leading biotechnology organization that transforms the lives of patients with devastating disease built around people with an outstanding track record in pharmaceutical research and development.
We are currently rallying together a small team of high-powered mentally agile team members to search for and evaluate assets using a series of robust clinical and commercial filters that will allow us to identify and acquire a portfolio of high-quality small molecule and protein-based assets in the late discovery to early clinical stages of drug development.
We are also raising capital from first class investors to support our operating costs and future development expenses and anticipate closing on our first round of financing in April 2018.
Leadership Team / Contacts:
Dr Martin Mackay
Dr Stephen Uden
Jeffrey Fryer CPA